EP1699472A1 - Agent actif pharmaceutique contre le cancer du sein - Google Patents
Agent actif pharmaceutique contre le cancer du seinInfo
- Publication number
- EP1699472A1 EP1699472A1 EP04786711A EP04786711A EP1699472A1 EP 1699472 A1 EP1699472 A1 EP 1699472A1 EP 04786711 A EP04786711 A EP 04786711A EP 04786711 A EP04786711 A EP 04786711A EP 1699472 A1 EP1699472 A1 EP 1699472A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- substance
- active
- enzyme
- synergistic
- antagonistic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000013543 active substance Substances 0.000 title claims abstract description 32
- 206010006187 Breast cancer Diseases 0.000 title claims abstract description 23
- 208000026310 Breast neoplasm Diseases 0.000 title claims abstract description 23
- 239000000126 substance Substances 0.000 claims abstract description 112
- 230000028327 secretion Effects 0.000 claims abstract description 47
- 241001465754 Metazoa Species 0.000 claims abstract description 22
- 230000001632 homeopathic effect Effects 0.000 claims abstract description 15
- 230000003042 antagnostic effect Effects 0.000 claims description 36
- 230000002195 synergetic effect Effects 0.000 claims description 32
- 239000004480 active ingredient Substances 0.000 claims description 30
- 108090000790 Enzymes Proteins 0.000 claims description 27
- 102000004190 Enzymes Human genes 0.000 claims description 27
- 229940088598 enzyme Drugs 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 20
- 230000000149 penetrating effect Effects 0.000 claims description 20
- 239000008186 active pharmaceutical agent Substances 0.000 claims description 14
- 231100000614 poison Toxicity 0.000 claims description 12
- 239000000243 solution Substances 0.000 claims description 12
- 238000011282 treatment Methods 0.000 claims description 12
- 239000002574 poison Substances 0.000 claims description 10
- 238000005194 fractionation Methods 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 6
- 102000001974 Hyaluronidases Human genes 0.000 claims description 5
- 102000015439 Phospholipases Human genes 0.000 claims description 4
- 108010064785 Phospholipases Proteins 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- 241000239292 Theraphosidae Species 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000003053 toxin Substances 0.000 claims description 4
- 231100000765 toxin Toxicity 0.000 claims description 4
- 108700012359 toxins Proteins 0.000 claims description 4
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 claims description 3
- 108010003272 Hyaluronate lyase Proteins 0.000 claims description 3
- 241000270426 Varanus Species 0.000 claims description 3
- 239000000824 cytostatic agent Substances 0.000 claims description 3
- 230000001085 cytostatic effect Effects 0.000 claims description 3
- 229960002773 hyaluronidase Drugs 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 241000876464 Varanus acanthurus Species 0.000 claims description 2
- 241000439555 Varanus gilleni Species 0.000 claims description 2
- 241000439523 Varanus kingorum Species 0.000 claims description 2
- 238000001042 affinity chromatography Methods 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 230000002365 anti-tubercular Effects 0.000 claims description 2
- 229940088710 antibiotic agent Drugs 0.000 claims description 2
- 229940121375 antifungal agent Drugs 0.000 claims description 2
- 239000000969 carrier Substances 0.000 claims description 2
- 239000012050 conventional carrier Substances 0.000 claims description 2
- 238000005227 gel permeation chromatography Methods 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 238000004255 ion exchange chromatography Methods 0.000 claims description 2
- 230000000394 mitotic effect Effects 0.000 claims description 2
- 244000045947 parasite Species 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 238000012545 processing Methods 0.000 claims description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 4
- 239000004471 Glycine Substances 0.000 claims 2
- 239000007983 Tris buffer Substances 0.000 claims 2
- 239000008367 deionised water Substances 0.000 claims 2
- 229910021641 deionized water Inorganic materials 0.000 claims 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims 1
- 229920000936 Agarose Polymers 0.000 claims 1
- 102000008100 Human Serum Albumin Human genes 0.000 claims 1
- 108091006905 Human Serum Albumin Proteins 0.000 claims 1
- 206010052428 Wound Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 239000011324 bead Substances 0.000 claims 1
- 238000010352 biotechnological method Methods 0.000 claims 1
- 230000002070 germicidal effect Effects 0.000 claims 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 1
- 238000004128 high performance liquid chromatography Methods 0.000 claims 1
- 239000000644 isotonic solution Substances 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 claims 1
- 239000012460 protein solution Substances 0.000 claims 1
- 241000270433 Varanidae Species 0.000 abstract description 24
- 206010028980 Neoplasm Diseases 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 230000000035 biogenic effect Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 238000002604 ultrasonography Methods 0.000 description 5
- 241000270322 Lepidosauria Species 0.000 description 4
- 241000270295 Serpentes Species 0.000 description 4
- 241000879315 Varanus komodoensis Species 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000009607 mammography Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 241000239290 Araneae Species 0.000 description 2
- 108050009363 Hyaluronidases Proteins 0.000 description 2
- 229910000831 Steel Inorganic materials 0.000 description 2
- 208000030270 breast disease Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000005865 ionizing radiation Effects 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 210000005075 mammary gland Anatomy 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000002976 pectoralis muscle Anatomy 0.000 description 2
- 239000010959 steel Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 210000003371 toe Anatomy 0.000 description 2
- 108010004032 Bromelains Proteins 0.000 description 1
- 208000004434 Calcinosis Diseases 0.000 description 1
- 241001466804 Carnivora Species 0.000 description 1
- 240000001829 Catharanthus roseus Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 241001503987 Clematis vitalba Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241000208125 Nicotiana Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 108010040201 Polymyxins Proteins 0.000 description 1
- 208000037062 Polyps Diseases 0.000 description 1
- 208000007660 Residual Neoplasm Diseases 0.000 description 1
- 241001455226 Sauria Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 241000270666 Testudines Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 241000098864 Varanus boehmei Species 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 238000007469 bone scintigraphy Methods 0.000 description 1
- 235000019835 bromelain Nutrition 0.000 description 1
- 229960001780 bromelains Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 210000003109 clavicle Anatomy 0.000 description 1
- 239000002642 cobra venom Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000001847 jaw Anatomy 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000003254 palate Anatomy 0.000 description 1
- 230000000803 paradoxical effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 230000036515 potency Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229940091258 selenium supplement Drugs 0.000 description 1
- 230000008786 sensory perception of smell Effects 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- 210000004894 snout Anatomy 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000002708 spider venom Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 210000005182 tip of the tongue Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- Breast cancer or breast cancer is a malignant one
- the skin looks a bit too big for the body because it is on the neck and
- Monitor lizards are good and fast runners.
- the antagonistic or synergistic substance is preferably a phospholipase or a hyaluronidase or a combination of both substances.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Marine Sciences & Fisheries (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L'invention concerne un agent actif pharmaceutique pour le traitement du cancer du sein, par combinaison d'une substance obtenue à partir de la sécrétion buccale d'animaux de la famille Varanidae, et d'une substance homéopathique.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10341307A DE10341307A1 (de) | 2003-09-08 | 2003-09-08 | Pharmarzeutischer Wirkstoff gegen Brustkrebs |
| PCT/DE2004/001988 WO2005023276A1 (fr) | 2003-09-08 | 2004-09-07 | Agent actif pharmaceutique contre le cancer du sein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP1699472A1 true EP1699472A1 (fr) | 2006-09-13 |
Family
ID=34223451
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP04786711A Withdrawn EP1699472A1 (fr) | 2003-09-08 | 2004-09-07 | Agent actif pharmaceutique contre le cancer du sein |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP1699472A1 (fr) |
| DE (2) | DE10341307A1 (fr) |
| WO (1) | WO2005023276A1 (fr) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1120007C (zh) * | 2000-10-23 | 2003-09-03 | 蔡一青 | 一种治疗乳腺疾病的药物 |
| CN1215862C (zh) * | 2002-11-04 | 2005-08-24 | 周宝义 | 一种治疗恶性肿瘤的中药饮液及制备方法 |
-
2003
- 2003-09-08 DE DE10341307A patent/DE10341307A1/de not_active Withdrawn
-
2004
- 2004-09-07 EP EP04786711A patent/EP1699472A1/fr not_active Withdrawn
- 2004-09-07 DE DE112004002232T patent/DE112004002232D2/de not_active Expired - Fee Related
- 2004-09-07 WO PCT/DE2004/001988 patent/WO2005023276A1/fr not_active Ceased
Non-Patent Citations (1)
| Title |
|---|
| See references of WO2005023276A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005023276A1 (fr) | 2005-03-17 |
| DE112004002232D2 (de) | 2006-07-27 |
| DE10341307A1 (de) | 2005-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1244462B1 (fr) | Preparation pharmaceutique a base de venin d'araignee, sa preparation et son utilisation pour traiter des affections tumorales | |
| CH404858A (de) | Verfahren zur Herstellung von wachstumfördernde Stoffe enthaltenden Präparaten | |
| WO2005023276A1 (fr) | Agent actif pharmaceutique contre le cancer du sein | |
| DE102005038768A1 (de) | Pharmazeutischer Wirkstoff gegen Borreliose | |
| WO2005009449A1 (fr) | Principe actif pharmaceutique agissant contre les verrues, l'herpes et le zona | |
| WO2006029605A1 (fr) | Procede et principe actif pour lutter contre les plasmodies | |
| EP2155335B1 (fr) | Composition pharmaceutique, utilisation de la composition pharmaceutique pour le traitement d'une tumeur du cerveau, procédé de fabrication de cette composition et kit contenant la composition pharmaceutique | |
| DE10357970A1 (de) | Lösungsmittel für biogene pharmazeutische Wirkstoffe | |
| WO2005007177A1 (fr) | Agent pharmaceutique servant a traiter des ulceres gastriques | |
| DE10330712A1 (de) | Pharmarzeutischer Wirkstoff gegen Kolonkarzinome und andere Tumorarten | |
| WO1994018957A2 (fr) | Utilisation de substances actives en therapie de certaines maladies, procede de preparation d'une composition pharmaceutique utile a cet effet et compositions pharmaceutiques ainsi preparees | |
| WO2007060252A2 (fr) | Agent pharmaceutique destine a traiter l'hepatite, la borreliose et la sclerose en plaques | |
| EP4233886A1 (fr) | Composition pharmaceutique pour le traitement d'une tumeur cérébrale | |
| EP1754486A2 (fr) | Substance pharmaceutique pour le traitement de l'Hépatitis, Borreliosis et Sclèrosis Multiple | |
| EP1699471A1 (fr) | Agent pharmaceutique contre l'hepatite | |
| WO2006032245A1 (fr) | Principe actif pharmaceutique contre le syndrome du vih | |
| DE10324062A1 (de) | Pharmazeutischer Wirkstoff | |
| DE10324861A1 (de) | Pharmazeutischer Wirkstoff | |
| WO2005027942A1 (fr) | Principe actif pharmaceutique provenant de venin de serpent, ce principe actif servant a traiter les melanomes | |
| WO2007071716A1 (fr) | Composition pharmaceutique utilisee pour traiter des tumeurs et des maladies virales definies | |
| WO2006081808A1 (fr) | Principe actif permettant de traiter la sclerose en plaques et le sida | |
| WO2006034691A1 (fr) | Substance pharmaceutique active servant a renforcer le systeme immunitaire | |
| DE10322656A1 (de) | Pharmazeutischer Wirkstoff | |
| WO2005002494A2 (fr) | Principe actif pharmaceutique pour lutter contre les carcinomes de la prostate | |
| WO2005120525A1 (fr) | Substance active pharmaceutique extraite de lycosa tarantula |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20060724 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR |
|
| 17Q | First examination report despatched |
Effective date: 20061024 |
|
| DAX | Request for extension of the european patent (deleted) | ||
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20080401 |